Axios @axios
In an interview with Axios, two Biogen executives insisted the company's unproven $55,000 Alzheimer's drug is priced fairly, and that it didn't conduct another clinical trial before approval because the FDA didn't push them to do so. https://t.co/nuKvFJiv1A — PolitiTweet.org